• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How to use immune checkpoint inhibitor in ovarian cancer?

作者信息

Park Junsik, Lee Jung Yun, Kim Sunghoon

机构信息

Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.

出版信息

J Gynecol Oncol. 2019 Sep;30(5):e105. doi: 10.3802/jgo.2019.30.e105.

DOI:10.3802/jgo.2019.30.e105
PMID:31328467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6658602/
Abstract
摘要

相似文献

1
How to use immune checkpoint inhibitor in ovarian cancer?如何在卵巢癌中使用免疫检查点抑制剂？
J Gynecol Oncol. 2019 Sep;30(5):e105. doi: 10.3802/jgo.2019.30.e105.
2
Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.原发性和复发性上皮性卵巢癌中的肿瘤相关巨噬细胞和肿瘤免疫微环境。
Hum Pathol. 2018 Apr;74:135-147. doi: 10.1016/j.humpath.2017.12.010. Epub 2017 Dec 27.
3
Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes.卵巢癌免疫检查点抑制剂相关毒性的诊断和管理：一系列病例简述。
Clin Ther. 2018 Mar;40(3):389-394. doi: 10.1016/j.clinthera.2018.02.011. Epub 2018 Mar 5.
4
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.抗PD-L1/PD-1免疫疗法在卵巢癌中的应用：基本机制与未来临床应用
Int J Clin Oncol. 2016 Jun;21(3):456-61. doi: 10.1007/s10147-016-0968-y. Epub 2016 Mar 11.
5
Trials show delayed recurrence in ovarian cancer.试验表明卵巢癌复发延迟。
Cancer Discov. 2013 Jun;3(6):OF8. doi: 10.1158/2159-8290.CD-ND2013-013. Epub 2013 Apr 18.
6
Immune checkpoint inhibition in ovarian cancer.卵巢癌中的免疫检查点抑制
Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7.
7
Management and Treatment of Recurrent Epithelial Ovarian Cancer.复发性上皮性卵巢癌的管理与治疗
Hematol Oncol Clin North Am. 2018 Dec;32(6):965-982. doi: 10.1016/j.hoc.2018.07.005.
8
Checkpoint inhibitors in immunotherapy of ovarian cancer.卵巢癌免疫治疗中的检查点抑制剂
Tumour Biol. 2015 Jan;36(1):33-9. doi: 10.1007/s13277-014-2848-2. Epub 2014 Nov 20.
9
Planning treatment for women with recurrent epithelial ovarian cancer.复发性上皮性卵巢癌女性的治疗规划。
Oncology (Williston Park). 2013 Apr;27(4):304, 306.
10
[Extension of recurrence-free and overall survival in patients with ovarian cancer stage III using hyperthermic intraperitoneal chemotherapy (HIPEC)].[采用腹腔热灌注化疗（HIPEC）对III期卵巢癌患者无复发生存期和总生存期的延长]
Strahlenther Onkol. 2018 Jul;194(7):695-696. doi: 10.1007/s00066-018-1311-5.

引用本文的文献

1
Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.卵巢肿瘤免疫肽组学的蛋白质基因组学方法鉴定出共享的肽疫苗候选物。
NPJ Vaccines. 2025 Aug 16;10(1):195. doi: 10.1038/s41541-025-01234-6.
2
Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis.铂耐药复发性卵巢癌的靶向药物治疗策略比较：贝叶斯网状Meta 分析。
Medicine (Baltimore). 2024 May 24;103(21):e38183. doi: 10.1097/MD.0000000000038183.
3
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.双靶融合蛋白 bintrafusp alfa 通过抑制 TGF-β 和 PD-L1 促进 T 效应细胞和 NK 细胞应答，从而提高临床前卵巢癌模型的存活率。
Br J Cancer. 2024 Jun;130(12):2003-2015. doi: 10.1038/s41416-024-02677-9. Epub 2024 Apr 15.
4
Cancer of unknown primary histologically, genetically and spatially diagnosed as left ovary‑derived cancer: A case report.组织学、遗传学和空间上诊断为源自左卵巢的原发性不明癌症：一例报告。
Oncol Lett. 2023 Oct 19;26(6):522. doi: 10.3892/ol.2023.14109. eCollection 2023 Dec.
5
Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvironment and Predicting the Immunotherapy Response.在卵巢癌肿瘤微环境中建立CD8 + T细胞相关基因的分子亚组并预测免疫治疗反应。
Biomedicines. 2023 Aug 28;11(9):2399. doi: 10.3390/biomedicines11092399.
6
Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis.卵巢癌患者综合基因组分析的实施：一项回顾性分析
Cancers (Basel). 2022 Dec 29;15(1):218. doi: 10.3390/cancers15010218.
7
Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.靶向钍 227 缀合物作为单一药物及联合抗 PD-L1 治疗的免疫刺激作用。
J Immunother Cancer. 2021 Oct;9(10). doi: 10.1136/jitc-2021-002387.
8
Ovarian Cancer Immunotherapy and Personalized Medicine.卵巢癌免疫治疗与个性化医学。
Int J Mol Sci. 2021 Jun 18;22(12):6532. doi: 10.3390/ijms22126532.
9
Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer.探讨肿瘤微环境在铂耐药性卵巢癌中的临床价值。
Semin Cancer Biol. 2021 Dec;77:83-98. doi: 10.1016/j.semcancer.2020.12.024. Epub 2021 Jan 18.
10
Quantifying the efficacy of checkpoint inhibitors on CD8 cytotoxic T cells for immunotherapeutic applications via single-cell interaction.通过单细胞相互作用量化免疫治疗应用中检查点抑制剂对 CD8 细胞毒性 T 细胞的疗效。
Cell Death Dis. 2020 Nov 13;11(11):979. doi: 10.1038/s41419-020-03173-7.

本文引用的文献

1
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.TIM-3决定卵巢癌中免疫浸润细胞的功能取向。
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831. doi: 10.1158/1078-0432.CCR-18-4175. Epub 2019 May 10.
2
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.铂耐药上皮性卵巢癌的 PD-1 抑制剂治疗的早期经验。
J Gynecol Oncol. 2019 Jul;30(4):e56. doi: 10.3802/jgo.2019.30.e56. Epub 2019 Feb 27.
3
Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.肿瘤浸润淋巴细胞和同源重组缺陷与卵巢癌患者生存改善独立相关。
Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.
4
Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.新辅助化疗后晚期高级别浆液性卵巢癌残余肿瘤中程序性细胞死亡配体 1 和免疫检查点标志物的表达。
Gynecol Oncol. 2018 Dec;151(3):414-421. doi: 10.1016/j.ygyno.2018.08.023. Epub 2018 Oct 9.
5
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.泛肿瘤基因组生物标志物用于基于 PD-1 检查点阻断的免疫治疗。
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
6
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.抗 PD-1 抗体纳武利尤单抗治疗铂耐药卵巢癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
7
PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.PD-1 和 CD103 在人卵巢癌中具有预后意义的上皮内 CD8 T 细胞上广泛共表达。
Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
8
CD25 identifies a subset of CD4⁺FoxP3⁻ TIL that are exhausted yet prognostically favorable in human ovarian cancer.CD25 鉴定了人卵巢癌中 CD4⁺FoxP3⁻ TIL 的衰竭亚群，但其预后有利。
Cancer Immunol Res. 2015 Mar;3(3):245-53. doi: 10.1158/2326-6066.CIR-14-0146. Epub 2014 Dec 5.
9
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.表达组织驻留记忆标志物 CD103 的肿瘤浸润淋巴细胞与高级别浆液性卵巢癌患者生存率的提高相关。
Clin Cancer Res. 2014 Jan 15;20(2):434-44. doi: 10.1158/1078-0432.CCR-13-1877. Epub 2013 Nov 4.
10
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.肿瘤浸润 T 细胞在卵巢癌中的预后意义：一项荟萃分析。
Gynecol Oncol. 2012 Feb;124(2):192-8. doi: 10.1016/j.ygyno.2011.09.039. Epub 2011 Oct 29.